Evaluation of Efficacy and Safety of Latanoprost/Timolol versus Travoprost/Timolol Fixed Combinations for Ocular Hypertension Associated with Uveitis

REFERENCES

• Merayo-Lloves J, Power WJ, Rodriguez A, et al. Secondary glaucoma in patients with uveitis. Ophthalmologica 1999;213:300–304.
   PubMed Web of Science ®Google Scholar
• Johnson D, Gottanka J, Flugel C, et al. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol 1997;115:375–383.
   PubMedGoogle Scholar
• Moorthy RS, Mermoud A, Baerveldt G, et al. Glaucoma associated with uveitis. Surv Ophthalmol 1997;41:361–394.
   PubMed Web of Science ®Google Scholar
• Herbert HM, Viswanathan A, Jackson H, et al. Risk factors for elevated intraocular pressure in uveitis. J Glaucoma 2004;13:96–99.
   PubMed Web of Science ®Google Scholar
• Kanda T, Shibata M, Taguchi M, et al. Prevalence and aetiology of ocular hypertension in acute and chronic uveitis. Br J Ophthalmol 2014;98:932–936.
   PubMed Web of Science ®Google Scholar
• Dunker S, Schmucker A, Maier H. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther 2007;24:376–386.
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120:915–922.
   PubMed Web of Science ®Google Scholar
• Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002;240:893–899.
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005;140:1–7.
   PubMed Web of Science ®Google Scholar
• Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987;103:234–235.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985;92:467–471.
   PubMed Web of Science ®Google Scholar
• Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17:183–190.
   PubMed Web of Science ®Google Scholar
• Shoji T, Sato H, Mizukawa A, et al. Hypotensive effect of latanoprost/timolol versus travoprost/timolol fixed combinations in NTG patients: a randomized, multicenter, crossover clinical trial. Invest Ophthalmol Vis Sci 2013;54:6242–6247.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology 2007;114:653–657.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Mikropoulos DG, Embeslidis TA, et al. 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Eye (Lond) 2010;24:1606–1613.
   PubMed Web of Science ®Google Scholar
• Rigollet JP, Ondategui JA, Pasto A, et al. Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate. Clin Ophthalmol 2011;5:187–91.
   PubMedGoogle Scholar
• Cheng J-W, Cheng S-W, Gao L-D, et al. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One 2012;7:e45079.
   Google Scholar
• Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003;19:501–515.
   PubMed Web of Science ®Google Scholar
• Ornek K, Onaran Z, Turgut Y. Anterior uveitis associated with fixed-combination latanoprost and timolol. Can J Ophthalmol 2008;43:727–728.
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126:37–41.
   PubMed Web of Science ®Google Scholar
• Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998;105:263–268.
   PubMed Web of Science ®Google Scholar
• Smith SL, Pruitt CA, Sine CS, et al. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999;77:668–672.
   PubMedGoogle Scholar
• Markomichelakis NN, Kostakou A, Halkiadakis I, et al. Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol 2009;247:775–780.
   PubMed Web of Science ®Google Scholar
• Fortuna E, Cervantes-Castaneda RA, Bhat P, et al. Flare-up rates with bimatoprost therapy in uveitic glaucoma. Am J Ophthalmol 2008;146:876–882.
   PubMed Web of Science ®Google Scholar
• Sallam A, Sheth HG, Habot-Wilner Z, et al. Outcome of raised intraocular pressure in uveitic eyes with and without a corticosteroid-induced hypertensive response. Am J Ophthalmol 2009;148:207–213.
   PubMed Web of Science ®Google Scholar
• Horsley MB, Chen TC. The use of prostaglandin analogs in the uveitic patient. Semin Ophthalmol 2011;26:285–289.
   PubMed Web of Science ®Google Scholar